|
DK2199390T3
(en)
|
2007-08-30 |
2017-04-03 |
Daiichi Sankyo Co Ltd |
ANTI-EphA2 ANTIBODY
|
|
EP2225275A4
(en)
*
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
SI2274008T1
(sl)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
WO2011003071A1
(en)
*
|
2009-07-02 |
2011-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods of modulating hepatitis c virus infection
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2498797A4
(en)
*
|
2009-11-09 |
2013-12-25 |
Brigham & Womens Hospital |
TREATMENT OF CARDIOPATHY
|
|
WO2011057249A2
(en)
|
2009-11-09 |
2011-05-12 |
The Brigham And Women's Hospital, Inc. |
Treatment of heart disease
|
|
CA2791905A1
(en)
|
2010-03-01 |
2011-09-09 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Biomarkers for theranostics
|
|
CA2795776A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Circulating biomarkers for disease
|
|
WO2012012759A2
(en)
*
|
2010-07-22 |
2012-01-26 |
The Regents Of The University Of California |
Anti-tumor antigen antibodies and methods of use
|
|
CN103052649B
(zh)
|
2010-07-29 |
2015-12-16 |
Xencor公司 |
具有修改的等电点的抗体
|
|
JP2014500879A
(ja)
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
|
|
RU2650775C2
(ru)
*
|
2011-08-23 |
2018-04-17 |
Рош Гликарт Аг |
Биспецифические антигенсвязывающие молекулы
|
|
US20130078250A1
(en)
*
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
NO2748201T3
(OSRAM)
*
|
2011-08-23 |
2018-05-12 |
|
|
|
EP2760892A1
(en)
*
|
2011-09-29 |
2014-08-06 |
Apo-T B.V. |
Multi-specific binding molecules targeting aberrant cells
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2860914A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
|
EP2820047B1
(en)
*
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Long life polypeptide binding molecules
|
|
AU2013302696B9
(en)
*
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US20160015749A1
(en)
*
|
2013-03-05 |
2016-01-21 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
EP2964241A1
(en)
*
|
2013-03-05 |
2016-01-13 |
Baylor College Of Medicine |
Oncolytic virus
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10544187B2
(en)
|
2013-03-15 |
2020-01-28 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
ES2742224T3
(es)
*
|
2013-11-07 |
2020-02-13 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos biespecíficos anti-WT1/HLA
|
|
KR20230004939A
(ko)
|
2014-02-07 |
2023-01-06 |
맥마스터 유니버시티 |
3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
|
|
EP3122781B1
(en)
|
2014-03-28 |
2020-01-01 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
HUE042829T2
(hu)
|
2014-04-03 |
2019-07-29 |
Igm Biosciences Inc |
Módosított J-lánc
|
|
KR102463529B1
(ko)
|
2014-04-10 |
2022-11-07 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
약물 관련 트랜스진 발현
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
JP6702893B2
(ja)
|
2014-06-27 |
2020-06-03 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的抗原結合タンパク質
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
MA41433A
(fr)
*
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
|
CA3225013A1
(en)
|
2015-02-24 |
2016-09-01 |
Bioatla, Llc |
Conditionally active proteins
|
|
PL3265575T3
(pl)
|
2015-03-04 |
2021-11-29 |
Igm Biosciences, Inc. |
Cząsteczki wiążące CD20 i ich zastosowania
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
|
JP7162530B2
(ja)
|
2015-08-07 |
2022-10-28 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
|
|
AU2016329197B2
(en)
|
2015-09-30 |
2021-01-21 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
CN108463472A
(zh)
*
|
2015-09-30 |
2018-08-28 |
Igm生物科学有限公司 |
具有修饰的j-链的结合分子
|
|
WO2017087789A1
(en)
|
2015-11-19 |
2017-05-26 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
WO2017100372A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
US11534466B2
(en)
|
2016-03-09 |
2022-12-27 |
Aal Scientifics, Inc. |
Pancreatic stem cells and uses thereof
|
|
HRP20250113T1
(hr)
|
2016-06-02 |
2025-03-28 |
Immunocore Limited |
Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
|
|
WO2017218707A2
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
EP3478321A4
(en)
|
2016-06-30 |
2020-04-22 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
MA46534A
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor Inc |
Protéines de fusion fc hétérodimères il15/il15r
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
WO2018213467A1
(en)
|
2017-05-16 |
2018-11-22 |
The Johns Hopkins University |
Manabodies and methods of using
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
EP3647433B1
(en)
*
|
2017-06-30 |
2023-04-12 |
Osaka University |
Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood t cells as index
|
|
IL302613B2
(en)
|
2017-09-08 |
2025-04-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
CN109879965B
(zh)
*
|
2017-12-06 |
2022-11-11 |
北京科立思维生物科技有限公司 |
抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用
|
|
MA51291A
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor Inc |
Protéines de fusion il-2 fc modifiées
|
|
JP2021508477A
(ja)
*
|
2017-12-29 |
2021-03-11 |
オンコラス， インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019222579A1
(en)
|
2018-05-17 |
2019-11-21 |
St. Jude Children's Research Hospital, Inc. |
Chimeric antigen receptors with myd88 and cd40 costimulatory domains
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
CN113614111A
(zh)
*
|
2019-01-14 |
2021-11-05 |
加利福尼亚大学董事会 |
用于调节细胞内化的组合物和方法
|
|
EP3918326A4
(en)
*
|
2019-01-31 |
2022-04-20 |
Siemens Healthcare Diagnostics, Inc. |
ANTI-NALOXONE AND ANTI-NALTREXONE MONOCLONAL ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF
|
|
BR112021016955A2
(pt)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
KR20230031981A
(ko)
|
2019-05-14 |
2023-03-07 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
KR20230092863A
(ko)
|
2020-06-11 |
2023-06-26 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
US12016923B2
(en)
|
2021-06-01 |
2024-06-25 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 T cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CN116970077A
(zh)
*
|
2021-07-16 |
2023-10-31 |
西南医科大学 |
一种抗EphA2全人源双价重组抗体scFv-Fc
|
|
JP2024527977A
(ja)
|
2021-07-27 |
2024-07-26 |
ノヴァブ， インコーポレイテッド |
免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
|